**Name of Journal: *World Journal of Stem Cells***

**Manuscript NO: 41840**

**Manuscript Type: MINIREVIEWS**

**Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells**

Radpour R *et al*. Molecular biomarkers for tumor cells

Ramin Radpour, Farzad Forouharkhou

**Ramin Radpour,** Tumor Immunology, Department for BioMedical Research (DBMR), University of Bern, Bern 3008, Switzerland

**Ramin Radpour,** Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern 3008, Switzerland

**Farzad Forouharkhou,** Department for Bioinformatics, Persian Bioinformatics System, Tehran 14166, Iran

**ORCID number:** Ramin Radpour (0000-0002-5632-7833); Farzad Forouharkhou (0000-0002-6249-6115).

**Author contributions:** Radpour R and Forouharkhou F wrote the paper.

**Conflict-of-interest statement:** There is no conflict of interest.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Ramin Radpour, MSc, PhD, Senior Researcher,** Tumor Immunology, Department for BioMedical Research (DBMR), University of Bern, Murtenstrasse 35, Bern 3008, Switzerland. ramin.radpour@dbmr.unibe.ch

**Telephone:** +41-31-6320956

**Fax:** +41-31-6323297

**Received:** August 30, 2018

**Peer-review started:** August 30, 2018

**First decision:** October 16, 2018

**Revised:** October 18, 2018

**Accepted:** October 23, 2018

**Article in press:**

**Published online:**

**Abstract**

Biomarker-driven individualized treatment in oncology has made tremendous progress through technological developments, new therapeutic modalities and a deeper understanding of the molecular biology for tumors, cancer stem cells (CSCs) and tumor-infiltrating immune cells. The recent technical developments have led to the establishment of a variety of cancer-related diagnostic, prognostic and predictive biomarkers. In this regard, different modern OMICs approaches were assessed in order to categorize and prognostically classify different forms of neoplasia. Despite those technical advancements, the extent of molecular heterogeneity at the individual cell level in human tumors remains largely uncharacterized. Each tumor consists of a mixture of heterogeneous cell types. Therefore, it is important to quantify the dynamic cellular variations in order to predict clinical parameters such as a response to treatment and or potential for disease recurrence. Recently, single-cell based methods have been developed to characterize the heterogeneity in seemingly homogenous cancer cell populations prior to and during treatment. In this review, we highlight the recent advances for single-cell analysis and discuss the challenges and prospects for molecular characterization of cancer cells, CSCs and tumor-infiltrating immune cells.

**Key words:** Cancer cells; Cancer stem cells; Cancer biomarkers; Tumor-infiltrating lymphocytes; Single-cell analysis

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip****:** Extensive heterogeneity in cancer cells negatively influences treatment efficacy and survival of patients. The existing molecular methods for biomarker discovery of cancer cells and cancer stem cells (CSCs) are often unsuited to capture the heterogeneous nature of cell populations. Recent advances in single-cell based profiling approaches allowed the detection of molecular changes in individual cancer cells. Therefore, single-cell analysis is leading to build a complete landscape of cell types within tumor cells and facilitating the study of complex molecular heterogeneity in cancer cell populations. This will improve the investigation of more specific biomarkers to identify and target CSCs.

Radpour R, Forouharkhou F. Single-cell analysis of tumor cells: Creating new value for molecular biomarker discovery of cancer stem cells. *World J Stem Cells* 2018; In press

**INTRODUCTION**

In principle, three main classes of biomarkers are distinguished for cancer disease stratification: diagnostic, prognostic and predictive biomarkers[1-4]. In oncology, the diagnostic biomarkers essentially serve to substantiate a specific entity association and suspected malignant disease-spreading pattern. Classical examples are the *in situ* immunophenotyping of a neoplasm such as lung cancer[5] by immunohistology as well as the specific representation of entity-defining molecules such as prostate-specific membrane antigen in prostate cancer[6].

By contrast, prognostic biomarkers have the function of predicting the natural course of a malignant disease. These include classical parameters such as clinical and pathological staging, but also the collection of molecular factors, such as tumor specific genetic aberrations (chromosomal abnormalities, gene mutations, pathologic epigenetic changes or dysregulated genes/pathways) that may be associated with more aggressive disease progression. However, a prognostic biomarker has only a limited value for the patient, since mere knowledge about the prognosis of disease alone has little benefit[2,4,7].

The predictive biomarkers specifically describe the expected likelihood of a patient responding to an available therapy option based on the molecular properties of the tumor. This concept is currently used in the context of targeted drug-based tumor treatment with targeted drugs, *e.g.* with inhibitors of the epidermal growth factor receptor (EGFR) in the presence of a tissue-based EGFR mutation in lung carcinomas[8] or CD70-CD27 signaling in leukemia including acute myeloid leukemia (AML)[9] or chronic myeloid leukemia (CML)[10]. However, there are only a few approved predictive biomarkers available which are usually tissue-based markers. Predictive analytics using molecular imaging and blood-based technologies is still at stage of development.

The boundaries between these biomarker types can be blurred. For example, a pathologic genetic alteration in different situations may represent a diagnostic, a prognostic, and a predictive biomarker. This is illustrated by the example of a *BRAF* mutation, it can support the early diagnosis of a thyroid carcinoma[11], prognostically define an unfavorable subtype of colorectal carcinoma[4] and predictably provide therapy with a BRAF-specific small molecule inhibitor (*e.g.*, vemurafenib) in malignant melanoma[12].

Classical macroscopically assisted histomorphologic evaluation of a malignant tumor, remains by far the most significant diagnostic, prognostic, and in many respects predictive biomarker with the greatest impact on patient treatment. Nevertheless, in recent decades, a refinement of biomarker analysis by molecular methods has found its way into pathological diagnostics and shaped the new area of individualized medicine.

**CANCER STEM CELLS**

Cancer stem cells (CSCs) or tumor precursor cells are a minor fraction of cells within the bulk tumor population which, because of their unique stem cell properties of relative quiescence and self-renewal, has been found to reconstitute and propagate the tumor and are considered to be essential for tumor neoplasm and metastasis[13]. The theory of CSCs was firstly postulated in the 1970s and was experimentally confirmed by the isolation of tumor-initiating cells in AML[14]. Furthermore, CSC has been demonstrated in a variety of solid tumors such as tumors in brain, colorectal, hematopoietic malignancies (*e.g*., myeloid or lymphoid leukemia), head and neck, mammary glands, lung, liver, melanoma and also prostate carcinomas[9,10,15,16]. Heterogeneity is a major hallmark of tumor cells including CSCs. Each cancer cell clone is characterized by harboring different combinations of mutations or genetic alterations and subsequently the processes of tumorigenesis occur differently based on the type of genetic lesions[17].

CSCs are often resistant against standard therapies such as irradiation, chemotherapy, cytotoxic drugs and probably also against immune attack. This may be due to different escape mechanisms of CSCs and/or due to protective mechanisms of the microenvironment. Unravelling the function of the CSCs has been one of the main challenges of the cancer research[16,18].

**HIGH-THROUGHPUT TECHNOLOGIES FOR PROFILING OF CANCER CELLS AND CSCs**

Over the past few decade, variety of biomarkers for a wide range of solid tumors and hematopoietic malignancies have been identified[2,4]. The technologies for biomarker analysis are developing rapidly. The next generation sequencing (NGS) technology, promptly follows some of the technologies mentioned above, which will lead to further dynamization of the biomarker discovery in oncology. In addition, blood-based assays using circulating cell free DNA (cfDNA) that move beyond the classic tumor marker determination will become more important for the monitoring of disease processes and resistances as well as the prediction of therapy outcome[16,19-21]. Mutational analysis in *EGFR*-mutated lung carcinoma prior to therapy with Osimertinib is an example of a blood-based assay that have already found way into the routine diagnostic pipelines[22]. Further assays, are developing to trace and target circulating tumor cells (mainly CSCs) in the blood, urine, cerebrospinal fluid and other body fluids. The goal must be to transfer molecular markers from tissue diagnostics into non-invasive molecular profiling approaches.

**MOLECULAR BIOMARKERS OF CANCER CELLS AND CSCs**

***Proteomics***

Targeted proteomics using tissue-based *in situ* methods such as immunohistology has been developed as an important biomarker analysis tool in oncology[23]. This approach is used in many areas of pathology including pathological oncology, and the predictive biomarker analysis still relying significantly on this method. Examples include the analysis of human epidermal growth factor receptor 2 (HER2) expression prior to treatment with HER2 inhibitors (*e.g.* trastuzumab) in gastric and breast carcinoma[24,25] as well as the stratifying assignment of treatment with immune checkpoint inhibitors in programmed death-ligand 1 (PD-L1)-positive advanced non-small cell lung cancer[26]. The development of multiplexable and quantitatively more precise proteomic methods promises new opportunities for biomarker discovery/analysis in the near future. These include using slice-based imaging mass spectrometry [*e.g.,* matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS)][27] or quantitative multiplex protein analysis using extract-based mass spectrometry (LC-MS)[28].

***Genomics***

The earliest clinically relevant genomic studies on predictive biomarker analysis used in routine diagnostics were the application of fluorescence *in situ* hybridizations (FISH) to determine the gene copy number of *ERBB2*, the *HER2* gene, in breast cancer which could assign it to a positive or negative category for *HER2* expression[2,29,30]. One of the first examples of a large solid tumor profiling is mutation screening for *KRAS* and *NRAS* genes in metastatic colorectal carcinoma as a predictive biomarker for using the EGFR inhibitor panitumumab[4,31]. Today, numerous individual examinations of gene mutations or chromosomal aberrations (*e.g.*, translocations or amplifications) are firmly anchored in the routine diagnostic of different tumors. Currently, new technologies such as massive parallel sequencing (MPS) have been priced into areas where routine diagnostic application has become possible. Those methods have already been adapted to high-throughput screening in routine applications[32]. Implementation of those high-throughput approaches leads to improvement of diagnosis and therapy of different cancer types[33,34].

***Epigenomics***

The first introduced epigenetic biomarker into the routine diagnostic was investigation of promoter methylation of the *MGMT* gene using sequence-based techniques, to predict response to treatment with temozolomide in glioblastoma[35]. However, newer epigenetic screening approaches, which are still in the process of diagnostic development, focus on the simultaneous investigation of DNA methylation in a large number of coding genes using array-based or high-throughput sequencing methods (*e.g.*,Methyl-seq). Since it is postulated that pathologic methylation patterns in individual tumor entities are more stable and reproducible than transcriptome profiles, these technologies are currently being tested primarily in molecular entity assignment. Large studies have substantiated their overall suitability for cancer with unknown primary and for some rare tumor families, but have not yet been implemented in the routine diagnostic pipelines[36-38].

***Transcriptomics***

The analysis of RNA expression signature within cancer cells and CSCs using quantitative polymerase chain reaction (qPCR), array-based capture, NanoString technology or massive parallel RNA sequencing (RNA-Seq) approaches has a long tradition in cancer molecular biomarker analysis. However, individual methods (*e.g.,* qPCR) could never prevail over immunohistology despite partially superior precision. Initially, the parallel analysis of RNA expression patterns was assessed hoping that diagnostic assignments could be made in unclear cases (*e.g.,* cancer with unknown primary)[39]. Despite their potential and some positive results, these applications could not establish themselves in the wide range of diagnostic services. In addition, many tumor entities have been used to develop predictors for the efficacy of conventional chemotherapies based on transcriptomic profiles. Some success in this context has been gene expression tests in breast cancer, which can be used as an additional decision-making aid in the therapy stratification of breast cancer patients for adjuvant chemotherapy[40]. However, these tests are currently not being used consistently in clinical care.

As indicated, tumors are a pool of heterogeneous cells including CSCs. Inter- or intra-tumor heterogeneity may completely render CSC biomarkers. Seemingly homogenous cell populations that are enriched and purified by a set of well-known surface markers, often hide exceptional heterogeneity. This is more pronounced in the hematological malignancies[16]. Such tumor heterogeneity can be the result of different genetically distinct clones within the tumor due to having various genetic lesions or dysregulation of markers via pathologic epigenetic regulations[2,4,41-46].

**SINGLE-CELL BASED APPROACHES**

Different OMICs approaches have allowed the discovery and characterization of the variety of cancer-related cell populations. However, those approaches are unsuited to capture the heterogeneous nature of cancer cell populations. Therefore, the interest was shifted towards characterization of single-cells rather than cell populations. The technical advances that includes single-cell imaging, genomics or transcriptomics, assessed fully characterization of different cell populations. The OMICs analysis is usually performed using samples of many cells. However, this type of analyses lacks the kind of detailed assessment needed for evaluating contribution of individual cells to the overall phenotype. In contrast, single-cell analysis allows comparing the captured OMICs data of thousands of individual cells (Figure 1). Applied methods for single-cell isolation have rapidly enhanced in the past few years from manual micromanipulation, cell-search antibody-based isolation or flow-sorting of cells to high-throughput isolation methods using DEP-arrays, microfluidics, emulsion-based platforms or 10X genomics ChromiumTM single cell controller system. This technical advance could provide massive advantages in terms of significantly increase the throughput sensitivity and accuracy of employed approaches (Figure 1B).

One of the prime reasons for using the single-cell analysis is to evaluate heterogeneity in seemingly homogenous cell populations. Another reason is to detect small subpopulations that would otherwise be missed in bulk populations. In addition, using the single-cell analysis, it is possible to find CSCs and trace them in the circulation, investigate the clonal evolution and mutational rate of cancer cells, to better study the invasion and trace the metastatic dissemination and also understanding the molecular mechanisms of therapy resistance of cancer cells and CSCs (Figure 2).

The first single-cell RNA-Seq study was published in 2009[47]. Since then the interest for the approach is growing[48,49]. Single-cell RNA sequencing is being used for identifying cellular intermediates during developmental processes. Different microfluidic systems have been proposed to isolate single cells and help in library preparation[50]. Several novel methods are available for single-cell analyses. Multiplexed error robust fluorescence (MERFISH), is a high-throughput method that uses sequential imaging with combinatorial labeling and multiplex single molecule FISH, allowing robust detection of many genes at the same time in both tissues and cell culture conditions[51]. Another approach is quantitative hybridization chain reaction (qHCR) which uses probes harboring initiators for DNA interacting with fluorophore-labelled hairpins assembled into polymerase. Using this method, the mRNA expression of thousands of different genes can be captured simultaneously at a single-cell based resolution[52]. Single-cell linage tracking, allows researchers to follow and trace the fate of individual cells over the time. This also includes the tracing of different cancer cells from primitive CSCs. Lineage tracing by nuclease-activated editing of ubiquitous sequences (LINNAEUS), is a novel method for cell type identification, characterization and massively parallel linage tracking. In this approach, a double strand break will be introduced to the cells using a CRISPR/Cas9 system which upon repair, reacts as a unique heritable scar in the daughter cells in order to trace the cellular linages[53].

Pooled screenings rely on readouts that average properties of the cell population of interest. Although these approaches provide an assessment of gene function at the genome scale, they cannot identify the contribution of subpopulations to the bulk phenotype. Moreover, the consequences of distinct perturbations to the overall phenotype cannot be evaluated. To circumvent the problem, methods have been recently developed to study the impact of perturbations at the single-cell levels[54,55]. These approaches integrate parallel massive single-cell RNA-Seq and pooled screens to reconstruct the gene regulatory networks controlling particular biological processes. Perturb-Seq is a platform for multiplexed profiling of perturbations at the single-cell resolution[54]. Profiling the genomic perturbation and the transcriptome in the same cell provides a powerful means to simultaneous identify the function of multiple factors and their interactions.

Heterogeneity in the tumor cell population was recently evaluated in different forms of human cancers. In the ovarian cancer, single-cell analysis revealed two major subsets of cells characterized by stromal gene expression patterns [genes associated with epithelial-to-mesenchymal transition (EMT) and also extracellular matrix (ECM) genes] and epithelial gene expression signature (characterized by proliferation- and oxidative phosphorylation-related genes)[56]. Analysis of CSCs in CML, uncovered distinct molecular signatures of leukemia stem cells with a high level of heterogeneity in the seemingly homogenous cell populations of CSCs[57]. Single-cell whole exome sequencing (scWES) is a promising tool for detecting sub-clones and possibly leukemia stem cells in AML[58]. Furthermore, epigenetically distinct hematopoietic stem cell sub-populations have been detected by high-resolution single-cell DNA methylation analysis[59]. Single-cell sequencing of glioblastoma and glioma cells also detected a heterogeneous gene expression signature within the tumor population[60,61]. In breast cancer, regulatory networks influencing stemness, pluripotency, proliferation, differentiation and EMT has been identified using single-cell gene expression profiling. The analysis has shown that ALDH-CD44+CD24- and ALDH+ human mammary cells have mesenchymal-like and epithelial-like characteristics, respectively. At the single-cell level, these cells express high levels of stemness- and EMT-associated gene signatures. In contrast, both detected populations had some co-expressing ALDH+ and CD44+CD24- by flow cytometry[62]. Important findings using single-cell sequencing studies on variety of human primary tumors including bladder, blood, brain, breast, colorectal, kidney, lung and ovarian cancer, are summarized in Table 1.

**SINGLE-CELL T CELL RECEPTOR SEQUENCING OF TUMOR-INFILTRATING LYMPHOCYTES**

Most immune cell types can be present in a tumor, and the fraction of immune cells can vary greatly across different tumors and patients[63]. T lymphocytes are among the most studied tumor-infiltrating immune cells since they have the potential to recognize mutated protein epitopes displayed by human lymphocyte antigen (HLA) molecules on cancer cells and CSCs, thereby allowing immune recognition of the tumor. Different types of tumor-infiltrating lymphocytes (TILs) have different effects. For instance, CD4+ Tregs have been associated with poor survival and have been demonstrated to play an immune-suppressive role[64]. Conversely, CD8+ T cells can mediate cytolytic activity against cancer cells or CSCs. However, cancer cells, particularly CSCs, evade immune recognition and elimination by TILs *via* various mechanisms, including loss of antigen and the expression of immune inhibitory molecules. Tumor-infiltrating CD8+ T cell are often anergic, as characterized by their exhaustion phenotype[65]. Overall, it is clear that complex relationships govern the interactions between immune cells and cancer cells or CSCs.

During T cells development in the thymus, they gain the ability to recognize many different foreign antigens. This ability is assessed by the expression of highly polymorphic surface T cell receptors (TCRs). The enormous diversity of TCRs is resulted by random combinations of genes’ segments encoding TCR chains [including variable (V), diversity (D), and joining (J) segments][66]. Molecular profiling and characterization of TCRs in TILs could describes T cell dynamics in different tumors[67].

TILs are typically studied by immunohistochemistry or by flow cytometry, relying on a panel of antibodies targeting specific markers of immune cells. To complement this approach, gene expression of whole tumors can be used and expression of the immune cell type markers can inform us about the presence of the corresponding cell types[68]. One promising aspect of this approach is that it provides information about the whole transcriptome and is not restricted by the availability of antibodies. While, it is not capable to overcome the extensive heterogeneity among TILs.

The NGS approach using genomic DNA (gDNA) as starting material, was first used to characterize the TCR diversity in healthy individuals[69] and rapidly adapted to TCR profiling in tumor immunology[70]. However, the use of gDNA was more challenging due to the fact that non-productive TCR rearrangements were also sequenced. In addition, the presence of introns can introduce more technical biases. Therefore, RNA-seq was selected as a better approach. Upon introducing more advanced single-cell analysis approaches like microfluidics or 10 × genomics, there was promise to couple RNA-seq and TCR sequencing from the same cell which had the great advantage to identify and characterize very rare T cell populations. A recent work using different single-cell analysis methods could investigate the T cell repertoire according to their TCR variability in both mice and human Treg cells[71]. The results of this comprehensive TCR single-cell sequencing reviled that Tregs with some highly-activated subpopulations can display a broad heterogeneity. While, Treg sharing the same antigen recognition specificity were more transcriptionally similar than those with different TCR sequence.

The coupled profiling of TCRs sequencing and single-cell gene expression analysis from the same cell, provides an unbiased classification of T cells based of their TCR signature which is association of the transcriptional landscape of individual cell[72]. This approach will provide a powerful tool to study the potential impact of TILs on CSCs and will result valuable insights to personalized immunotherapy of cancer patients.

**CONCLUSION**

The determination of diagnostic, prognostic and predictive biomarkers forms the basis of an individualization for patient treatment in oncology. As a biomarker, it is demanded to be reproducible, robust and quality-assured. Since today, the collection of specific biomarkers will not be able to define the complete subsequent of oncological therapy for the cancer patients. This affects the efficacy of a treatment, the side effects that a patient is exposed to, and the cost of therapy.

Despite some developments in the field of blood-based tests and molecular imaging, biomarker analysis in oncology continues to rely essentially on molecular tissue analysis. An exact molecular characterization of CSCs in the tumor requires the development of specific markers and suitable enrichment methods. New genomics, epigenomics, transcriptomics and proteomics methods as well as the introduction of novel single-cell based approached will result in an accelerating identification of specific oncological biomarkers.

Single-cell technologies are allowing the detection of molecular changes in the individual cancer cells. This can improve investigation of more specific biomarkers with unprecedented resolution leading to build a complete landscape of different cell types within tumors. Single-cell analysis of CSCs is challenging mainly due to their rarity and the small amount of total RNA in a single cell. Using a combination of different cellular enrichment strategies such as flow cytometry for rare cell population like CSCs, with the single-cell analyzing methods, will improve the resolution in profiling and characterization of CSCs. Likewise, the ability to amplify and sequence other RNA molecules such as micro RNAs and long non-coding RNAs, will provide valuable information on gene regulation. New methods to simultaneously profile genomic DNA variants, DNA methylation and gene expression from the same cell coupled with potential proteomic analysis, could provide powerful tools for assessing the effects of genomic variation and gene expression profiles or epigenetic modifications on cancer cell heterogeneity. Particularly, from high-throughput single-cell based technologies, we can expect valuable insights regarding suitable associated biomarkers to identify and target CSCs. Furthermore, cancer immunotherapy may also benefit from single-cell methods that define the role of TILs within the CSCs and monitor the individual response to the immune-regulatory agents. This would be an important step towards individualized cancer management.

**REFERENCES**

1 **Biomarkers Definitions Working Group**. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001; **69**: 89-95 [PMID: 11240971 DOI: 10.1067/mcp.2001.113989]

2 **Radpour R**, Barekati Z, Kohler C, Holzgreve W, Zhong XY. New trends in molecular biomarker discovery for breast cancer. *Genet Test Mol Biomarkers* 2009; **13**: 565-571 [PMID: 19814613 DOI: 10.1089/gtmb.2009.0060]

3 **Zhang B**, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, Zhong XY. Proteomics and biomarkers for ovarian cancer diagnosis. *Ann Clin Lab Sci* 2010; **40**: 218-225 [PMID: 20689132]

4 **Aghagolzadeh P**, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. *World J Gastroenterol* 2016; **22**: 5678-5693 [PMID: 27433083 DOI: 10.3748/wjg.v22.i25.5678]

5 **Warth A**, Muley T, Herpel E, Meister M, Herth FJ, Schirmacher P, Weichert W, Hoffmann H, Schnabel PA. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. *Histopathology* 2012; **61**: 1017-1025 [PMID: 22882703 DOI: 10.1111/j.1365-2559.2012.04308.x]

6 **Maurer T**, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. *Nat Rev Urol* 2016; **13**: 226-235 [PMID: 26902337 DOI: 10.1038/nrurol.2016.26]

7 **Nalejska E**, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. *Mol Diagn Ther* 2014; **18**: 273-284 [PMID: 24385403 DOI: 10.1007/s40291-013-0077-9]

8 **Tan DS**, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. *J Thorac Oncol* 2016; **11**: 946-963 [PMID: 27229180 DOI: 10.1016/j.jtho.2016.05.008]

9 **Riether C**, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, Zlobec I, Pabst T, Radpour R, Ochsenbein AF. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. *J Exp Med* 2017; **214**: 359-380 [PMID: 28031480 DOI: 10.1084/jem.20152008]

10 **Riether C**, Schürch CM, Flury C, Hinterbrandner M, Drück L, Huguenin AL, Baerlocher GM, Radpour R, Ochsenbein AF. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. *Sci Transl Med* 2015; **7**: 298ra119 [PMID: 26223302 DOI: 10.1126/scitranslmed.aab1740]

11 **Tennakoon TMPB**, Rushdhi M, Ranasinghe ADCU, Dassanayake RS. Values of molecular markers in the differential diagnosis of thyroid abnormalities. *J Cancer Res Clin Oncol* 2017; **143**: 913-931 [PMID: 28008451 DOI: 10.1007/s00432-016-2319-9]

12 **Bollag G**, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* 2010; **467**: 596-599 [PMID: 20823850 DOI: 10.1038/nature09454]

13 **Dawood S**, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. *Oncology* (Williston Park) 2014; **28**: 1101-1107, 1110 [PMID: 25510809]

14 **Lapidot T**, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994; **367**: 645-648 [PMID: 7509044 DOI: 10.1038/367645a0]

15 **Visvader JE**, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 2008; **8**: 755-768 [PMID: 18784658 DOI: 10.1038/nrc2499]

16 **Radpour R**. Tracing and targeting cancer stem cells: New venture for personalized molecular cancer therapy. *World J Stem Cells* 2017; **9**: 169-178 [PMID: 29104735 DOI: 10.4252/wjsc.v9.i10.169]

17 **Meacham CE**, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. *Nature* 2013; **501**: 328-337 [PMID: 24048065 DOI: 10.1038/nature12624]

18 **Murone M**, Radpour R, Attinger A, Chessex AV, Huguenin AL, Schürch CM, Banz Y, Sengupta S, Aguet M, Rigotti S, Bachhav Y, Massière F, Ramachandra M, McAllister A, Riether C. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells. *Mol Cancer Ther* 2017; **16**: 1497-1510 [PMID: 28468777 DOI: 10.1158/1535-7163.mct-16-0889]

19 **Wan JCM**, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nat Rev Cancer* 2017; **17**: 223-238 [PMID: 28233803 DOI: 10.1038/nrc.2017.7]

20 **Zachariah RR**, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. *Obstet Gynecol* 2008; **112**: 843-850 [PMID: 18827127 DOI: 10.1097/AOG.0b013e3181867bc0]

21 **Zachariah R**, Schmid S, Radpour R, Buerki N, Fan AX, Hahn S, Holzgreve W, Zhong XY. Circulating cell-free DNA as a potential biomarker for minimal and mild endometriosis. *Reprod Biomed Online* 2009; **18**: 407-411 [PMID: 19298741]

22 **Mok TS**, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med* 2017; **376**: 629-640 [PMID: 27959700 DOI: 10.1056/NEJMoa1612674]

23 **Prichard JW**. Overview of automated immunohistochemistry. *Arch Pathol Lab Med* 2014; **138**: 1578-1582 [PMID: 25427039 DOI: 10.5858/arpa.2014-0083-RA]

24 **Cameron D**, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet* 2017; **389**: 1195-1205 [PMID: 28215665 DOI: 10.1016/S0140-6736(16)32616-2]

25 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

26 **Hui R**, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. *Ann Oncol* 2017; **28**: 874-881 [PMID: 28168303 DOI: 10.1093/annonc/mdx008]

27 **Kriegsmann M**, Casadonte R, Kriegsmann J, Dienemann H, Schirmacher P, Hendrik Kobarg J, Schwamborn K, Stenzinger A, Warth A, Weichert W. Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. *Mol Cell Proteomics* 2016; **15**: 3081-3089 [PMID: 27473201 DOI: 10.1074/mcp.M115.057513]

28 **Panis C**, Pizzatti L, Souza GF, Abdelhay E. Clinical proteomics in cancer: Where we are. *Cancer Lett* 2016; **382**: 231-239 [PMID: 27561426 DOI: 10.1016/j.canlet.2016.08.014]

29 **Piccart-Gebhart MJ**, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005; **353**: 1659-1672 [PMID: 16236737 DOI: 10.1056/NEJMoa052306]

30 **Radpour R**, Sikora M, Grussenmeyer T, Kohler C, Barekati Z, Holzgreve W, Lefkovits I, Zhong XY. Simultaneous isolation of DNA, RNA, and proteins for genetic, epigenetic, transcriptomic, and proteomic analysis. *J Proteome Res*2009; **8**: 5264-5274 [PMID: 19780627 DOI: 10.1021/pr900591w]

31 **Amado RG**, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]

32 **Endris V**, Stenzinger A, Pfarr N, Penzel R, Möbs M, Lenze D, Darb-Esfahani S, Hummel M, Sabine-Merkelbach-Bruse, Jung A, Lehmann U, Kreipe H, Kirchner T, Büttner R, Jochum W, Höfler G, Dietel M, Weichert W, Schirmacher P. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. *Virchows Arch* 2016; **468**: 697-705 [PMID: 27003155 DOI: 10.1007/s00428-016-1919-8]

33 **Jesinghaus M**, Pfarr N, Endris V, Kloor M, Volckmar AL, Brandt R, Herpel E, Muckenhuber A, Lasitschka F, Schirmacher P, Penzel R, Weichert W, Stenzinger A. Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. *Genes Chromosomes Cancer* 2016; **55**: 505-521 [PMID: 26917275 DOI: 10.1002/gcc.22352]

34 **Haghighi MM**, Radpour R, Mahmoudi T, Mohebbi SR, Vahedi M, Zali MR. Association between MTHFR polymorphism (C677T) with nonfamilial colorectal cancer. *Oncol Res* 2009; **18**: 57-63 [PMID: 20066895]

35 **Wick W**, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. MGMT testing--the challenges for biomarker-based glioma treatment. *Nat Rev Neurol* 2014; **10**: 372-385 [PMID: 24912512 DOI: 10.1038/nrneurol.2014.100]

36 **Moran S**, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. *Lancet Oncol* 2016; **17**: 1386-1395 [PMID: 27575023 DOI: 10.1016/S1470-2045(16)30297-2]

37 **Röhrich M**, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT, Bewerunge-Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, Perry A, Mautner VF, Mechtersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hänggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss DE. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathol* 2016; **131**: 877-887 [PMID: 26857854 DOI: 10.1007/s00401-016-1540-6]

38 **Radpour R**, Barekati Z, Haghighi MM, Kohler C, Asadollahi R, Torbati PM, Holzgreve W, Zhong XY. Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. *Mod Pathol* 2010; **23**: 763-772 [PMID: 20081803 DOI: 10.1038/modpathol.2009.195]

39 **Stenzinger A**, Kriegsmann M, Weichert W. [The role of pathology in the diagnostics of CUP syndrome]. *Radiologe* 2014; **54**: 124-133 [PMID: 24463713 DOI: 10.1007/s00117-013-2546-x]

40 **Harris LN**, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016; **34**: 1134-1150 [PMID: 26858339 DOI: 10.1200/JCO.2015.65.2289]

41 **Radpour R**, Haghighi MM, Fan AX, Torbati PM, Hahn S, Holzgreve W, Zhong XY. High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. *Mol Cancer Res* 2008; **6**: 1702-1709 [PMID: 19010818 DOI: 10.1158/1541-7786.MCR-08-0262]

42 **Radpour R**, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. *Oncogene* 2009; **28**: 2969-2978 [PMID: 19503099 DOI: 10.1038/onc.2009.149]

43 **Barekati Z**, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P, Lv Q, Zheng H, Zhong XY. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. *Hum Mol Genet*2010; **19**: 2936-2946 [PMID: 20466735 DOI: 10.1093/hmg/ddq199]

44 **Radpour R**, Barekati Z, Kohler C, Schumacher MM, Grussenmeyer T, Jenoe P, Hartmann N, Moes S, Letzkus M, Bitzer J, Lefkovits I, Staedtler F, Zhong XY. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. *PLoS One* 2011; **6**: e27355 [PMID: 22076154 DOI: 10.1371/journal.pone.0027355]

45 **Radpour R**, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. *PLoS One* 2011; **6**: e16080 [PMID: 21283676 DOI: 10.1371/journal.pone.0016080]

46 **Barekati Z**, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P, Zhong XY. Methylation signature of lymph node metastases in breast cancer patients. *BMC Cancer* 2012; **12**: 244 [PMID: 22695536 DOI: 10.1186/1471-2407-12-244]

47 **Tang F**, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, Wang X, Bodeau J, Tuch BB, Siddiqui A, Lao K, Surani MA. mRNA-Seq whole-transcriptome analysis of a single cell. *Nat Methods* 2009; **6**: 377-382 [PMID: 19349980 DOI: 10.1038/nmeth.1315]

48 **Haque A**, Engel J, Teichmann SA, Lönnberg T. A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications. *Genome Med* 2017; **9**: 75 [PMID: 28821273 DOI: 10.1186/s13073-017-0467-4]

49 **Macosko EZ**, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, Tirosh I, Bialas AR, Kamitaki N, Martersteck EM, Trombetta JJ, Weitz DA, Sanes JR, Shalek AK, Regev A, McCarroll SA. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell* 2015; **161**: 1202-1214 [PMID: 26000488 DOI: 10.1016/j.cell.2015.05.002]

50 **Ziegenhain C**, Vieth B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, Leonhardt H, Heyn H, Hellmann I, Enard W. Comparative Analysis of Single-Cell RNA Sequencing Methods. *Mol Cell* 2017; **65**: 631-643.e4 [PMID: 28212749 DOI: 10.1016/j.molcel.2017.01.023]

51 **Moffitt JR**, Hao J, Bambah-Mukku D, Lu T, Dulac C, Zhuang X. High-performance multiplexed fluorescence in situ hybridization in culture and tissue with matrix imprinting and clearing. *Proc Natl Acad Sci U S A* 2016; **113**: 14456-14461 [PMID: 27911841 DOI: 10.1073/pnas.1617699113]

52 **Trivedi V**, Choi HMT, Fraser SE, Pierce NA. Multidimensional quantitative analysis of mRNA expression within intact vertebrate embryos. *Development* 2018; **145**: [PMID: 29311262 DOI: 10.1242/dev.156869]

53 **Spanjaard B**, Hu B, Mitic N, Olivares-Chauvet P, Janjuha S, Ninov N, Junker JP. Simultaneous lineage tracing and cell-type identification using CRISPR-Cas9-induced genetic scars. *Nat Biotechnol* 2018; **36**: 469-473 [PMID: 29644996 DOI: 10.1038/nbt.4124]

54 **Adamson B**, Norman TM, Jost M, Cho MY, Nuñez JK, Chen Y, Villalta JE, Gilbert LA, Horlbeck MA, Hein MY, Pak RA, Gray AN, Gross CA, Dixit A, Parnas O, Regev A, Weissman JS. A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. *Cell* 2016; **167**: 1867-1882.e21 [PMID: 27984733 DOI: 10.1016/j.cell.2016.11.048]

55 **Datlinger P**, Rendeiro AF, Schmidl C, Krausgruber T, Traxler P, Klughammer J, Schuster LC, Kuchler A, Alpar D, Bock C. Pooled CRISPR screening with single-cell transcriptome readout. *Nat Methods* 2017; **14**: 297-301 [PMID: 28099430 DOI: 10.1038/nmeth.4177]

56 **Winterhoff BJ**, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. *Gynecol Oncol* 2017; **144**: 598-606 [PMID: 28111004 DOI: 10.1016/j.ygyno.2017.01.015]

57 **Giustacchini A**, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe Å, Qian H, Olsson-Strömberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. *Nat Med* 2017; **23**: 692-702 [PMID: 28504724 DOI: 10.1038/nm.4336]

58 **Walter C**, Pozzorini C, Reinhardt K, Geffers R, Xu Z, Reinhardt D, von Neuhoff N, Hanenberg H. Single-cell whole exome and targeted sequencing in NPM1/FLT3 positive pediatric acute myeloid leukemia. *Pediatr Blood Cancer* 2018; **65**: [PMID: 29090521 DOI: 10.1002/pbc.26848]

59 **Hui T**, Cao Q, Wegrzyn-Woltosz J, O'Neill K, Hammond CA, Knapp DJHF, Laks E, Moksa M, Aparicio S, Eaves CJ, Karsan A, Hirst M. High-Resolution Single-Cell DNA Methylation Measurements Reveal Epigenetically Distinct Hematopoietic Stem Cell Subpopulations. *Stem Cell Reports* 2018; **11**: 578-592 [PMID: 30078558 DOI: 10.1016/j.stemcr.2018.07.003]

60 **Sen R**, Dolgalev I, Bayin NS, Heguy A, Tsirigos A, Placantonakis DG. Single-Cell RNA Sequencing of Glioblastoma Cells. *Methods Mol Biol* 2018; **1741**: 151-170 [PMID: 29392698 DOI: 10.1007/978-1-4939-7659-1\_12]

61 **Johnson E**, Dickerson KL, Connolly ID, Hayden Gephart M. Single-Cell RNA-Sequencing in Glioma. *Curr Oncol Rep* 2018; **20**: 42 [PMID: 29637300 DOI: 10.1007/s11912-018-0673-2]

62 **Colacino JA**, Azizi E, Brooks MD, Harouaka R, Fouladdel S, McDermott SP, Lee M, Hill D, Madden J, Boerner J, Cote ML, Sartor MA, Rozek LS, Wicha MS. Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. *Stem Cell Reports* 2018; **10**: 1596-1609 [PMID: 29606612 DOI: 10.1016/j.stemcr.2018.03.001]

63 **Fridman WH**, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer* 2012; **12**: 298-306 [PMID: 22419253 DOI: 10.1038/nrc3245]

64 **Curiel TJ**, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 2004; **10**: 942-949 [PMID: 15322536 DOI: 10.1038/nm1093]

65 **Baitsch L**, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, Rufer N, Speiser DE. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. *J Clin Invest* 2011; **121**: 2350-2360 [PMID: 21555851 DOI: 10.1172/JCI46102]

66 **Schatz DG**, Ji Y. Recombination centres and the orchestration of V(D)J recombination. *Nat Rev Immunol* 2011; **11**: 251-263 [PMID: 21394103 DOI: 10.1038/nri2941]

67 **Kirsch IR**, Watanabe R, O'Malley JT, Williamson DW, Scott LL, Elco CP, Teague JE, Gehad A, Lowry EL, LeBoeuf NR, Krueger JG, Robins HS, Kupper TS, Clark RA. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. *Sci Transl Med* 2015; **7**: 308ra158 [PMID: 26446955 DOI: 10.1126/scitranslmed.aaa9122]

68 **Bindea G**, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013; **39**: 782-795 [PMID: 24138885 DOI: 10.1016/j.immuni.2013.10.003]

69 **Robins HS**, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. *Blood* 2009; **114**: 4099-4107 [PMID: 19706884 DOI: 10.1182/blood-2009-04-217604]

70 **Sherwood AM**, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, Herpel E, Kloor M, Ulrich A, Schneider M, Ulrich CM, Robins H. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. *Cancer Immunol Immunother* 2013; **62**: 1453-1461 [PMID: 23771160 DOI: 10.1007/s00262-013-1446-2]

71 **Zemmour D**, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. *Nat Immunol* 2018; **19**: 291-301 [PMID: 29434354 DOI: 10.1038/s41590-018-0051-0]

72 **De Simone M**, Rossetti G, Pagani M. Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges. *Front Immunol* 2018; **9**: 1638 [PMID: 30072991 DOI: 10.3389/fimmu.2018.01638]

73 **Zhang X**, Zhang M, Hou Y, Xu L, Li W, Zou Z, Liu C, Xu A, Wu S. Single-cell analyses of transcriptional heterogeneity in squamous cell carcinoma of urinary bladder. *Oncotarget* 2016; **7**: 66069-66076 [PMID: 27602771 DOI: 10.18632/oncotarget.11803]

74 **Li Y**, Xu X, Song L, Hou Y, Li Z, Tsang S, Li F, Im KM, Wu K, Wu H, Ye X, Li G, Wang L, Zhang B, Liang J, Xie W, Wu R, Jiang H, Liu X, Yu C, Zheng H, Jian M, Nie L, Wan L, Shi M, Sun X, Tang A, Guo G, Gui Y, Cai Z, Li J, Wang W, Lu Z, Zhang X, Bolund L, Kristiansen K, Wang J, Yang H, Dean M, Wang J. Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. *Gigascience* 2012; **1**: 12 [PMID: 23587365 DOI: 10.1186/2047-217X-1-12]

75 **Bakker B**, Taudt A, Belderbos ME, Porubsky D, Spierings DC, de Jong TV, Halsema N, Kazemier HG, Hoekstra-Wakker K, Bradley A, de Bont ES, van den Berg A, Guryev V, Lansdorp PM, Colomé-Tatché M, Foijer F. Single-cell sequencing reveals karyotype heterogeneity in murine and human malignancies. *Genome Biol* 2016; **17**: 115 [PMID: 27246460 DOI: 10.1186/s13059-016-0971-7]

76 **Gawad C**, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. *Proc Natl Acad Sci U S A* 2014; **111**: 17947-17952 [PMID: 25425670 DOI: 10.1073/pnas.1420822111]

77 **Boyd AL**, Aslostovar L, Reid J, Ye W, Tanasijevic B, Porras DP, Shapovalova Z, Almakadi M, Foley R, Leber B, Xenocostas A, Bhatia M. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. *Cancer Cell* 2018; **34**: 483-498.e5 [PMID: 30205048 DOI: 10.1016/j.ccell.2018.08.007]

78 **Hughes AE**, Magrini V, Demeter R, Miller CA, Fulton R, Fulton LL, Eades WC, Elliott K, Heath S, Westervelt P, Ding L, Conrad DF, White BS, Shao J, Link DC, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Walter MJ, Graubert TA. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. *PLoS Genet* 2014; **10**: e1004462 [PMID: 25010716 DOI: 10.1371/journal.pgen.1004462]

79 **Hou Y**, Song L, Zhu P, Zhang B, Tao Y, Xu X, Li F, Wu K, Liang J, Shao D, Wu H, Ye X, Ye C, Wu R, Jian M, Chen Y, Xie W, Zhang R, Chen L, Liu X, Yao X, Zheng H, Yu C, Li Q, Gong Z, Mao M, Yang X, Yang L, Li J, Wang W, Lu Z, Gu N, Laurie G, Bolund L, Kristiansen K, Wang J, Yang H, Li Y, Zhang X, Wang J. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. *Cell* 2012; **148**: 873-885 [PMID: 22385957 DOI: 10.1016/j.cell.2012.02.028]

80 **Shepherd MS**, Li J, Wilson NK, Oedekoven CA, Li J, Belmonte M, Fink J, Prick JCM, Pask DC, Hamilton TL, Loeffler D, Rao A, Schröder T, Göttgens B, Green AR, Kent DG. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal. *Blood* 2018; **132**: 791-803 [PMID: 29991556 DOI: 10.1182/blood-2017-12-821066]

81 **Francis JM**, Zhang CZ, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, Homer H, Haidar S, Blumenstiel B, Pedamallu CS, Ligon AH, Love JC, Meyerson M, Ligon KL. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. *Cancer Discov* 2014; **4**: 956-971 [PMID: 24893890 DOI: 10.1158/2159-8290.CD-13-0879]

82 **Patel AP**, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* 2014; **344**: 1396-1401 [PMID: 24925914 DOI: 10.1126/science.1254257]

83 **Baslan T**, Kendall J, Ward B, Cox H, Leotta A, Rodgers L, Riggs M, D'Italia S, Sun G, Yong M, Miskimen K, Gilmore H, Saborowski M, Dimitrova N, Krasnitz A, Harris L, Wigler M, Hicks J. Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. *Genome Res* 2015; **25**: 714-724 [PMID: 25858951 DOI: 10.1101/gr.188060.114]

84 **Lei B**, Zhang XY, Zhou JP, Mu GN, Li YW, Zhang YX, Pang D. Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker. *Tumour Biol* 2016; **37**: 14757-14764 [PMID: 27629143 DOI: 10.1007/s13277-016-5351-0]

85 **Nguyen A**, Yoshida M, Goodarzi H, Tavazoie SF. Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness. *Nat Commun* 2016; **7**: 11246 [PMID: 27138336 DOI: 10.1038/ncomms11246]

86 **Gao R**, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, Meric-Bernstam F, Michor F, Navin NE. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. *Nat Genet*2016; **48**: 1119-1130 [PMID: 27526321 DOI: 10.1038/ng.3641]

87 **Kim C**, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. *Cell* 2018; **173**: 879-893.e13 [PMID: 29681456 DOI: 10.1016/j.cell.2018.03.041]

88 **Wang Y**, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. *Nature* 2014; **512**: 155-160 [PMID: 25079324 DOI: 10.1038/nature13600]

89 **Yu C**, Yu J, Yao X, Wu WK, Lu Y, Tang S, Li X, Bao L, Li X, Hou Y, Wu R, Jian M, Chen R, Zhang F, Xu L, Fan F, He J, Liang Q, Wang H, Hu X, He M, Zhang X, Zheng H, Li Q, Wu H, Chen Y, Yang X, Zhu S, Xu X, Yang H, Wang J, Zhang X, Sung JJ, Li Y, Wang J. Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. *Cell Res* 2014; **24**: 701-712 [PMID: 24699064 DOI: 10.1038/cr.2014.43]

90 **Liu M**, Di J, Liu Y, Su Z, Jiang B, Wang Z, Su X. Comparison of EpCAMhighCD44+ cancer stem cells with EpCAMhighCD44- tumor cells in colon cancer by single-cell sequencing. *Cancer Biol Ther* 2018; **19**: 939-947 [PMID: 29580161 DOI: 10.1080/15384047.2018.1456605]

91 **Liu M**, Liu Y, Di J, Su Z, Yang H, Jiang B, Wang Z, Zhuang M, Bai F, Su X. Multi-region and single-cell sequencing reveal variable genomic heterogeneity in rectal cancer. *BMC Cancer* 2017; **17**: 787 [PMID: 29169336 DOI: 10.1186/s12885-017-3777-4]

92 **Kim KT**, Lee HW, Lee HO, Song HJ, Jeong da E, Shin S, Kim H, Shin Y, Nam DH, Jeong BC, Kirsch DG, Joo KM, Park WY. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. *Genome Biol* 2016; **17**: 80 [PMID: 27139883 DOI: 10.1186/s13059-016-0945-9]

93 **Guo X**, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing R, Gao R, Zhang L, Dong M, Hu X, Ren X, Kirchhoff D, Roider HG, Yan T, Zhang Z. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. *Nat Med* 2018; **24**: 978-985 [PMID: 29942094 DOI: 10.1038/s41591-018-0045-3]

94 **Xu X**, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, He W, Zeng L, Xing M, Wu R, Jiang H, Liu X, Cao D, Guo G, Hu X, Gui Y, Li Z, Xie W, Sun X, Shi M, Cai Z, Wang B, Zhong M, Li J, Lu Z, Gu N, Zhang X, Goodman L, Bolund L, Wang J, Yang H, Kristiansen K, Dean M, Li Y, Wang J. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. *Cell* 2012; **148**: 886-895 [PMID: 22385958 DOI: 10.1016/j.cell.2012.02.025]

95 **Kim KT**, Lee HW, Lee HO, Kim SC, Seo YJ, Chung W, Eum HH, Nam DH, Kim J, Joo KM, Park WY. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. *Genome Biol* 2015; **16**: 127 [PMID: 26084335 DOI: 10.1186/s13059-015-0692-3]

96 **Suzuki A**, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. *Genome Biol* 2015; **16**: 66 [PMID: 25887790 DOI: 10.1186/s13059-015-0636-y]

**P-Reviewer:** Economescu M, Garg M, Wang YG, Van Seuningen IM

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Cell and tissue engineering

**Country of origin:** Switzerland

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C


Grade D (Fair): 0

Grade E (Poor): 0


**Table 1 Single-cell sequencing studies on variety of human tumors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Tumor type** | **Source** | **Platform** | **Major finding** | **Ref.** |
| Bladder cancer | Squamous cell carcinoma | RNA-seq | Cellular heterogeneity in the gene expression affects the disease outcome. | [73] |
| Muscle-invasive cell carcinoma | SNV-seq | lineage-specific mutations are driving cancer initiation and progress. | [74] |
| Blood cancer | B-cell ALL | CNV-seq | CNVs were developed as an impact of environmental stressors, which was only detectable at single-cell level. | [75] |
| Pediatric ALL | SNV-seq | Analysis revealed clonal somatic mutational prevalence at single-cell resolution. | [76] |
| Therapy resistant AML | RNA-seq | Identified molecular signature of resistant LSCs versus therapy-naive LSCs. | [77] |
| Secondary AML | SNV-seq | Genomic complexity was identified at single cells which was not seen at bulk leukemic populations. | [78] |
| CML | RNA-seq | Single-cell analysis uncovered molecular signature of LSCs | [57] |
| JAK2 negative MPN | SNV-seq | Large genetic distances was observed between mono-clonal tumor cells. | [79] |
| JAK2V617F MPN | RNA-seq | Single-cell sequencing revealed the molecular networks driving self-renewal of CSCs. | [80] |
| Brain cancer | *EGFR* amplified GBM | CNV-seq | Heterogeneity in *EGFR* mutations among different tumor cells leading to variation in therapy response. | [81] |
| GBM | RNA-seq | Heterogeneity in gene expression panthers was identified including *EGFR* gene. | [82] |
| Breast cancer | ER+ | CNV-seq | Showed clonal evolution of tumor cells at single-cell resolution. | [83] |
| HER2+ | RNA-seq | 404 differentially expressed gene signature was identified in CSCs which had a prognostic value. | [84] |
| MDA-MB-231 and CN34 cell lines | RNA-seq | Gene expression profiling identifies small sub-population with more metastatic potential which was therapy resistant. | [85] |
| TNBC | CNV-seq  RNA-seq | Showed clonal evolution of tumor cells at single-cell level. Also chemo-resistance evolution in TNBC was identified | [86,87] |
| TNBC or ER+ HER2- | SNV-seq CNV-seq | ER+ HER2- tumors represented significantly less mutational rate compared to TNBC tumors. | [88] |
| Colorectal cancer | Colon tumor and adjacent normal cells | SNV-seq | Different mutational profiles were identified among tumors’ sub-populations. | [89] |
| Colon tumor | CNV-seq | CSCs (EpCAMhighCD44+) and DTCs (EpCAMhighCD44-) had similar somatic CNV pattern while they had regional differences. | [90] |
| Rectal tumor | CNV-seq | Multi-region single-cell analysis showed somatic copy number alterations are an early event in cancer development. | [91] |
| Kidney cancer | ccRCC primary carcinoma and paired metastasis | RNA-seq | Heterogeneity in the expression of targetable genes was identified. The finding highlights the necessity of multi-agent therapies. | [92] |
| Lung cancer | NSCLC | RNA-seq | Characterization of tumor-infiltrating T cells revealed that inter-tissue effector T cells with a highly migratory nature. | [93] |
| Clear cell renal cell carcinoma | SNV-seq | A complex mutational pattern was observed at single-cells compared to bulk tumors. | [94] |
| Adenocarcinoma PDX | RNA-seq | Single-cell sequencing identified KRAS+ drug resistant cell population within the tumor. | [95] |
| LC2/ad and LC2/ad-R cell lines | RNA-seq | Gene expression profiling identifies signature that is linked to therapy resistance. | [96] |
| Ovarian cancer | HGSOC | RNA-seq | Single-cell analysis could distinguish two major sub-populations within the tumor based on their gene expression signature. | [56] |

ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ccRCC: Clear cell renal cell carcinoma; CML: Chronic myeloid leukemia; CNV: Copy number variant; CSC: Cancer stem cell; DTC: Differentiated tumor cells; HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; EGFR: Epidermal growth factor receptor; GBM: Glioblastoma; HGSOC: High grade serous ovarian carcinomas; JAK2: Janus kinase 2; KRAS: Kirsten rat sarcoma viral oncogene homolog; LSC: Leukemia stem cell; MPN: Myeloproliferative neoplasm; NSCLC: Non-small-cell lung carcinoma; PDX: Patient-derived xenograft; SNV: Single nucleotide variant; TNBC: Triple negative breast cancer.



**Figure 1 Single-cell analysis of cancer cells cancer stem cells.** A: Cancer cells, in particular cancer stem cells (CSCs), represent **a** complex process of invasion, epithelial-mesenchymal transition (EMT), shedding into the blood stream (intravasation), mesenchymal-epithelial transition (MET) and invasion of circulating CSCs to the other tissues (extravasation); B: These CSCs can be isolated or also purified and enriched using different approaches based on their known molecular markers for variety of solid tumors or hematopoietic malignancies; C: Those enriched CSCs will be subjected to the single-cell based transcriptomic analysis. Upon sequencing, a pool of mapped reads will be analyzed based on the possible similarity to either sort the single cells to show how different cells are differentiated from more primitive ones, or will be sub-clustered according to their gene expression differences in order to dissect heterogeneous cell populations. CC: Cancer cell; CSC: Cancer stem cell; EMT: Epithelial-mesenchymal transition; MET: Mesenchymal-epithelial transition.



**Figure 2 Main applications of single-cell based profiling in cancer research.** A:Resolving intratumor heterogeneity; B: Finding and profiling cancer stem cells (CSCs) within the bulk tumor; C: Tracing circulating CSCs; D: Study extravasation or intravasation and cell plasticity in invasive and metastatic cancer cells; E: Investigating clonal evolution in tumor cells based on their linage differentiation or mutational prevalence; F: Discovery the mechanism of therapy resistance at a single-cell level. G: Single-cell T cell receptor (TCR) sequencing of tumor-infiltrating lymphocyte. CC: Cancer cell; CSC: Cancer stem cell; EMT: Epithelial-mesenchymal transition; MET: Mesenchymal-epithelial transition; TCR: T cell receptor; TIL: Tumor-infiltrating lymphocyte.